Immix Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Immix Biopharma
IMMX Stock  USD 2.10  0.06  2.94%   
Immix Biopharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Immix Biopharma's valuation are provided below:
Market Capitalization
58.1 M
Earnings Share
(0.76)
We have found one hundred twenty available fundamental trends for Immix Biopharma, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to confirm all of Immix Biopharma regular market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 33.6 M in 2025. Enterprise Value is likely to drop to about 24.8 M in 2025
Check Immix Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immix Biopharma's main balance sheet or income statement drivers, such as Tax Provision of 21.8 K, Net Interest Income of 1.1 M or Depreciation And Amortization of 6.6 K, as well as many indicators such as Dividend Yield of 0.0, Ptb Ratio of 4.93 or Book Value Per Share of 0.27. Immix financial statements analysis is a perfect complement when working with Immix Biopharma Valuation or Volatility modules.
  
Build AI portfolio with Immix Stock
Check out the analysis of Immix Biopharma Correlation against competitors.
For more information on how to buy Immix Stock please use our How to Invest in Immix Biopharma guide.

Immix Biopharma Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets14.2 M22.9 M6.3 M
Slightly volatile
Short and Long Term Debt Total1.9 M967.3 K3.1 M
Slightly volatile
Other Current Liabilities3.4 M3.2 M837 K
Slightly volatile
Total Current Liabilities4.4 M8.7 M4.3 M
Very volatile
Property Plant And Equipment Net2.9 M2.7 M360 K
Slightly volatile
Accounts Payable5.7 M5.4 M968.3 K
Slightly volatile
Cash12.4 M17.7 M5.4 M
Slightly volatile
Non Current Assets Total2.9 M2.8 M368.4 K
Slightly volatile
Cash And Short Term Investments12.4 M17.7 M5.4 M
Slightly volatile
Net Receivables1.4 M1.3 M381.4 K
Slightly volatile
Common Stock Shares Outstanding15.3 M28.3 M8.1 M
Slightly volatile
Liabilities And Stockholders Equity14.2 M22.9 M6.3 M
Slightly volatile
Other Current Assets30.7 K32.3 K196.2 K
Slightly volatile
Other Stockholder Equity47.2 M88.3 M19.3 M
Slightly volatile
Total Liabilities10.2 M9.7 M4.8 M
Pretty Stable
Property Plant And Equipment Gross2.9 M2.8 M366 K
Slightly volatile
Short and Long Term Debt42.8 K45 K2.8 M
Slightly volatile
Total Current Assets13.7 M20.2 M6 M
Slightly volatile
Capital Stock1.5 K2.8 K793
Slightly volatile
Short Term Debt55.8 K58.7 K2.8 M
Slightly volatile
Common Stock1.5 K2.8 K793
Slightly volatile
Property Plant Equipment5.3 K3.2 K7.8 K
Slightly volatile
Current Deferred Revenue274.3 K308.6 K336.4 K
Slightly volatile
Other Liabilities380 K427.5 K466.1 K
Slightly volatile

Immix Biopharma Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Tax Provision21.8 K41 K20.4 K
Pretty Stable
Depreciation And Amortization6.6 K6.3 K2.3 K
Slightly volatile
Selling General Administrative12 M11.4 M2.4 M
Slightly volatile
Other Operating Expenses19.5 M18.6 M4.5 M
Slightly volatile
Research Development11.9 M11.3 M2.6 M
Slightly volatile
Cost Of Revenue6.6 K6.3 K2.3 K
Slightly volatile
Total Operating Expenses23.8 M22.7 M5.1 M
Slightly volatile
Reconciled Depreciation121.2 K115.4 K16.1 K
Slightly volatile
Income Tax Expense22.3 K41 K20.6 K
Pretty Stable
Selling And Marketing Expenses5.2 K5.8 K6.3 K
Slightly volatile

Immix Biopharma Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow9.2 M17.5 M4 M
Slightly volatile
Depreciation121.2 K115.4 K16.2 K
Slightly volatile
Total Cash From Financing Activities13.5 M15.9 M6 M
Slightly volatile
End Period Cash Flow12.4 M17.7 M5.4 M
Slightly volatile
Change To Netincome681.8 K717.7 K2 M
Pretty Stable

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation5.3610.20636.4256
Very volatile
Payables Turnover0.00330.00340.006
Slightly volatile
Cash Per Share0.570.62510.4237
Slightly volatile
Days Payables Outstanding90.4 K86.1 K74.5 K
Pretty Stable
Income Quality0.470.67260.7069
Slightly volatile
Current Ratio2.212.3257.1063
Pretty Stable
Capex Per Share0.04370.04160.0071
Slightly volatile
Average Receivables290.7 K527.5 K202.1 K
Slightly volatile
Interest Debt Per Share0.04150.04370.8222
Slightly volatile
Debt To Assets0.05120.05393.205
Slightly volatile
Days Of Payables Outstanding90.4 K86.1 K74.5 K
Pretty Stable
Pretax Profit Margin0.07340.08260.0901
Slightly volatile
Ebt Per Ebit0.910.95512.2284
Pretty Stable
Operating Profit Margin0.07340.08260.0901
Slightly volatile
Ebit Per Revenue0.07340.08260.0901
Slightly volatile
Quick Ratio2.212.3257.1063
Pretty Stable
Net Income Per E B T1.10.9981.0201
Very volatile
Cash Ratio1.932.03546.7643
Pretty Stable
Operating Cash Flow Sales Ratio0.06620.07450.0812
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.821.08071.0002
Slightly volatile
Debt Ratio0.05120.05393.205
Slightly volatile
Net Profit Margin0.07350.08270.0902
Slightly volatile
Gross Profit Margin0.80.90.9813
Slightly volatile

Immix Biopharma Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap33.6 M56 M33.9 M
Slightly volatile
Enterprise Value24.8 M41.1 M32 M
Very volatile

Immix Fundamental Market Drivers

Cash And Short Term Investments17.7 M

Immix Upcoming Events

25th of March 2024
Upcoming Quarterly Report
View
10th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
25th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Immix Biopharma Financial Statements

Immix Biopharma investors use historical fundamental indicators, such as Immix Biopharma's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Immix Biopharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue308.6 K274.3 K
Cost Of Revenue6.3 K6.6 K
Stock Based Compensation To Revenue(0.01)(0.01)
Sales General And Administrative To Revenue(0.04)(0.04)
Research And Ddevelopement To Revenue(0.04)(0.04)
Revenue Per Share(6.09)(6.39)
Ebit Per Revenue 0.08  0.07 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
AMTAmerican Tower Corp
HLTOYHellenic Telecommunications Org
NFLXNetflix

Additional Tools for Immix Stock Analysis

When running Immix Biopharma's price analysis, check to measure Immix Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immix Biopharma is operating at the current time. Most of Immix Biopharma's value examination focuses on studying past and present price action to predict the probability of Immix Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immix Biopharma's price. Additionally, you may evaluate how the addition of Immix Biopharma to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY